Search results for "neuromyelitis optica spectrum disorder"

showing 2 items of 2 documents

Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.

2017

Background: Up to every fourth woman with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) suffers a clinically relevant relapse during pregnancy. High doses of steroids bear some serious risks, especially within the first trimester of pregnancy. Immunoadsorption (IA) is an effective and more selective treatment option in disabling MS relapse than plasma exchange. Data on the use of IA during pregnancy and breastfeeding are scarce. Methods: In this retrospective multicenter study, we analyzed the safety and efficacy of IA treatment in acute relapses during pregnancy or breastfeeding. The primary outcome parameter - change of acute relapse-related disability after IA…

Pediatricsmedicine.medical_specialtybreastfeedingBreastfeeding030204 cardiovascular system & hematologymultiple sclerosislcsh:RC346-42903 medical and health sciences0302 clinical medicineplasma exchangeHigh dosesMedicineIn patientSpectrum disorderImmunoadsorptionlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyrelapsePregnancytherapyNeuromyelitis opticabusiness.industryMultiple sclerosisneuromyelitis optica spectrum disordermedicine.diseaseeye diseasesNeurologyNeurology (clinical)pregnancybusiness030217 neurology & neurosurgeryimmunoadsorptionTherapeutic advances in neurological disorders
researchProduct

Clinical and MRI measures to identify non-acute MOG-antibody disease in adults

2022

Abstract MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG antibodies is unavailable or shows uncertain results. We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin 4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of patients with MOG-antibody disease in clinical practice. In this cross-sectional retrospective study, data from 16 MAGNIMS centres were i…

aquaporin 4-antibody positive neuromyelitis optica spectrum disorder; differential diagnosis; imaging; multiple sclerosis; myelin oligodendrocyte glycoprotein antibody-associated diseaseaquaporin 4-antibody positive neuromyelitis optica spectrum disordermyelin oligodendrocyte glycoprotein antibody-associated diseasedifferential diagnosisimagingNeurology (clinical)multiple sclerosis
researchProduct